Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

34.52
-0.1200-0.35%
Post-market: 34.520.00000.00%19:59 EDT
Volume:6.91M
Turnover:238.47M
Market Cap:24.94B
PE:-73.45
High:34.95
Open:34.64
Low:34.26
Close:34.64
52wk High:37.97
52wk Low:11.94
Shares:722.41M
Float Shares:581.00M
Volume Ratio:0.55
T/O Rate:1.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.5400
ROE:-8.52%
ROA:-16.48%
PB:5.89
PE(LYR):-63.93

Loading ...

Roivant President, Immunovant CEO Eric Venker disposes common shares worth $7.23 million

Reuters
·
May 23

Should Roivant’s One‑Off Driven Profitability Shift Require Action From Roivant Sciences (ROIV) Investors?

Simply Wall St.
·
May 22

Roivant Sciences Price Target Maintained With a $34.00/Share by HC Wainwright & Co.

Dow Jones
·
May 21

Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Kindly MD (NAKA) and Roivant Sciences (ROIV)

TIPRANKS
·
May 21

Roivant Sciences Ltd : Leerink Partners Raises Target Price to $42 From $38

THOMSON REUTERS
·
May 21

Immunovant director Atul Pande disposes 6,000 shares for $192,000

Reuters
·
May 21

BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Hasbro, Micron

Reuters
·
May 21

Stock Track | Roivant Sciences Soars 15.99% Intraday on Unexpected Q4 Profit and Promising Arthritis Drug Data

Stock Track
·
May 21

Roivant Sciences rises 15.2%

TIPRANKS
·
May 21

BUZZ-U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, AMC Entertainment, Roivant

Reuters
·
May 20

2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug -- Barrons.com

Dow Jones
·
May 20

BUZZ-Roivant rises as arthritis drug shows early promise

Reuters
·
May 20

Movement Alert|Roivant Sciences Rises 11.1% in Regular Trading, Business Progress Updates Drive Positive Market Reaction Despite Revenue Miss

Market Focus
·
May 20

Roivant Sciences Ltd reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 20

Immunovant Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 20

Movement Alert|Roivant Sciences Rises 8.12% in Pre-Market Trading, Reports Fiscal Q4 Results and Business Updates

Market Focus
·
May 20

S&P 500 Futures Rise In Premarket Trading; Immunovant, ImmunityBio Lead

Dow Jones
·
May 20

Roivant Sciences Swings to Fiscal Q4 Net Income, Revenue Decreases

MT Newswires Live
·
May 20

Stock Track | Roivant Sciences Soars 9.89% in Pre-Market on Unexpected Q4 Profit from Moderna Lawsuit Settlement

Stock Track
·
May 20

Immunovant Inc Q4 net loss misses on higher R&D costs

Reuters
·
May 20